Advertisement

Biomarkers and Optimal Management of Heart Failure in the Aging Population

  • Hanna K. GagginEmail author
  • James L. JanuzziJr.
Chapter

Abstract

The incidence of heart failure (HF) increases with advancing age with a lifetime risk for the diagnosis of 20 %. There are physiological changes that predispose the elderly to developing HF and small insults may rapidly precipitate decompensation of symptoms. There are special challenges in diagnosing and managing elderly patients with HF, challenges that biomarkers can help mitigate. Natriuretic peptides such as B-type natriuretic peptide and N-terminal proBNP are established biomarkers that have been proven to accurately diagnose and prognosticate HF. There are additional promising novel biomarkers that may be of use.

Keywords

Heart Failure Natriuretic Peptide Atrial Natriuretic Peptide Pulmonary Capillary Wedge Pressure Acute Heart Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

ACC

American College of Cardiology

ACE

Angiotensin converting enzyme

ADHERE

Acute Decompensated Heart Failure National Registry

AHA

American Heart Association

ANP

Atrial natriuretic peptide

ARB

Angiotensin II receptor blockers

BACH

Biomarkers in Acute Heart Failure

BATTLESCARRED

The NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death

BNP

B-type natriuretic peptide

CHS

Cardiovascular Health Study

GDF

Growth differentiation factor

HF

Heart failure

HFpEF

Heart failure with preserved ejection fraction

hsTnT

Highly sensitive troponin T

LVSD

Left ventricular systolic dysfunction

MR-proADM

Mid-regional pro adrenomedullin

MR-proANP

Mid-regional pro atrial natriuretic peptide

NP

Natriuretic peptide(s)

NT-proBNP

Amino-terminal B-type natriuretic peptide

PCWP

Pulmonary capillary wedge pressure

PRIDE

ProBNP Investigation of Dyspnea in the Emergency Department

PROTECT

ProBNP Outpatient Tailored Chronic Heart Failure Therapy

REDHOT

Rapid Emergency Department Heart Failure Outpatient Trial

sST2

Soluble ST2

TIME-CHF

Trial of Intensified versus Standard Medical therapy in Elderly Patients with Congestive HF

Val-HeFT

Valsartan Heart Failure

References

  1. 1.
    Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004;25(18):1614–9. Epub 2004/09/08.PubMedCrossRefGoogle Scholar
  2. 2.
    Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. Epub 2002/12/11.PubMedCrossRefGoogle Scholar
  3. 3.
    Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26(6):447–62. Epub 2008/05/21.PubMedCrossRefGoogle Scholar
  4. 4.
    Hajdu MA, Heistad DD, Siems JE, Baumbach GL. Effects of aging on mechanics and composition of cerebral arterioles in rats. Circ Res. 1990;66(6):1747–54. Epub 1990/06/01.PubMedCrossRefGoogle Scholar
  5. 5.
    Robert L. Aging of the vascular-wall and atherosclerosis. Exp Gerontol. 1999;34(4):491–501. Epub 2000/05/19.PubMedCrossRefGoogle Scholar
  6. 6.
    Taddei S, Virdis A, Ghiadoni L, Salvetti G, Bernini G, Magagna A, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38(2):274–9. Epub 2001/08/18.PubMedCrossRefGoogle Scholar
  7. 7.
    Linzbach AJ, Akuamoa-Boateng E. [Changes in the aging human heart. I. Heart weight in the aged] Die Alternsveranderungen des menschlichen Herzens. I. Das Herzgewicht im Alter. Klin Wochenschr. 1973;51(4):156–63. Epub 1973/02/15.PubMedCrossRefGoogle Scholar
  8. 8.
    Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68(6):1560–8. Epub 1991/06/01.PubMedCrossRefGoogle Scholar
  9. 9.
    Janczewski AM, Lakatta EG. Modulation of sarcoplasmic reticulum Ca(2+) cycling in systolic and diastolic heart failure associated with aging. Heart Fail Rev. 2010;15(5):431–45. Epub 2010/04/27.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73(2):413–67. Epub 1993/04/01.PubMedGoogle Scholar
  11. 11.
    Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol. 2008;52(7):534–40. Epub 2008/08/09.PubMedCrossRefGoogle Scholar
  12. 12.
    Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. The relationship between left ventricular systolic function and congestive heart failure diagnosed by clinical criteria. Circulation. 1988;77(3):607–12. Epub 1988/03/01.PubMedCrossRefGoogle Scholar
  13. 13.
    Tresch DD. Clinical manifestations, diagnostic assessment, and etiology of heart failure in elderly patients. Clin Geriatr Med. 2000;16(3):445–56. Epub 2000/08/05.PubMedCrossRefGoogle Scholar
  14. 14.
    Chronic Conditions: Making the case for ongoing care. September 2004 update. Johns Hopkins and the Robert Wood Johnson Foundation’s Partnership for Solutions [cited 2012 October 1]. Available from: http://www.partnershipforsolutions.org/DMS/files/chronicbook2004.pdf. Last Accessed on 25 Oct 2012
  15. 15.
    Kitzman DW. Heart failure with normal systolic function. Clin Geriatr Med. 2000;16(3):489–512. Epub 2000/08/05.PubMedCrossRefGoogle Scholar
  16. 16.
    McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350(9081):829–33. Epub 1997/10/06.PubMedCrossRefGoogle Scholar
  17. 17.
    Weinhouse GL. Pulmonary artery catheterization: Indications and complications. 2012 [updated May 15, 2012; cited 2012 October 3]; UpToDate. Available from: http://www.uptodate.com/contents/pulmonary-artery-catheterization-indications-and-complications?source=search_result&search=right+heart+cath&selectedTitle=2%7E150#H8. Last Accessed on 25 Oct 2012.
  18. 18.
    Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46. Epub 2007/08/19.PubMedCrossRefGoogle Scholar
  19. 19.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90. Epub 2009/04/11.PubMedCrossRefGoogle Scholar
  20. 20.
    Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25. Epub 2005/01/12.PubMedCrossRefGoogle Scholar
  21. 21.
    Rochon P. Drug prescribing for older adults. UpToDate, Inc.; 2012. http://www.uptodate.com/contents/drug-prescribing-for-older-adults. Last Accessed on 25 Oct 2012.
  22. 22.
    Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119(14):e391–479. Epub 2009/03/28.PubMedCrossRefGoogle Scholar
  23. 23.
    Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357–68. Epub 2007/12/25.PubMedCrossRefGoogle Scholar
  24. 24.
    Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991;87(4):1402–12.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Palmer SC, Yandle TG, Nicholls MG, Frampton CM, Richards AM. Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma. Eur J Heart Fail. 2009;11(9):832–9.PubMedCrossRefGoogle Scholar
  26. 26.
    van Kimmenade RR, Januzzi Jr JL, Bakker JA, Houben AJ, Rennenberg R, Kroon AA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol. 2009;53(10):884–90. Epub 2009/03/07.PubMedCrossRefGoogle Scholar
  27. 27.
    Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993;16(7):553–7. Epub 1993/07/01.PubMedCrossRefGoogle Scholar
  28. 28.
    Januzzi Jr JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95(8):948–54. Epub 2005/04/12.PubMedCrossRefGoogle Scholar
  29. 29.
    Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–7. Epub 2002/07/19.PubMedCrossRefGoogle Scholar
  30. 30.
    Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001;141(3):367–74. Epub 2001/03/07.PubMedCrossRefGoogle Scholar
  31. 31.
    Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47(3):582–6. Epub 2006/02/07.PubMedCrossRefGoogle Scholar
  32. 32.
    Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47(1):91–7. Epub 2006/01/03.PubMedCrossRefGoogle Scholar
  33. 33.
    McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41(3):571–9. Epub 2003/03/04.PubMedCrossRefGoogle Scholar
  34. 34.
    Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27(3):330–7. Epub 2005/11/19.PubMedCrossRefGoogle Scholar
  35. 35.
    Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90(3):254–8. Epub 2002/07/20.PubMedCrossRefGoogle Scholar
  36. 36.
    Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol. 2006;47(2):345–53. Epub 2006/01/18.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40(5):976–82. Epub 2002/09/13.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim HN, Januzzi Jr JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123(18):2015–9. Epub 2011/05/11.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350(7):655–63. Epub 2004/02/13.PubMedCrossRefGoogle Scholar
  40. 40.
    McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension. 2006;47(5):874–80. Epub 2006/04/06.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing. J Am Coll Cardiol. 2010;55(5):441–50. Epub 2010/02/02.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49(19):1943–50. Epub 2007/05/15.PubMedCrossRefGoogle Scholar
  43. 43.
    Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44(6):1328–33.PubMedCrossRefGoogle Scholar
  44. 44.
    Januzzi Jr JL, Sakhuja R, O'Donoghue M, Baggish AL, Anwaruddin S, Chae CU, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166(3):315–20. Epub 2006/02/16.PubMedCrossRefGoogle Scholar
  45. 45.
    Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem. 2006;52(8):1528–38. Epub 2006/06/17.PubMedCrossRefGoogle Scholar
  46. 46.
    Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52(12):997–1003. Epub 2008/09/13.PubMedCrossRefGoogle Scholar
  47. 47.
    Kim HN, Januzzi Jr JL. Biomarkers in the management of heart failure. Curr Treat Opt Cardiovasc Med. 2010;12(6):519–31. Epub 2010/11/11.CrossRefGoogle Scholar
  48. 48.
    Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J. 2009;158(3):422–30. Epub 2009/08/25.PubMedCrossRefGoogle Scholar
  49. 49.
    Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med. 2010;170(6):507–14. Epub 2010/03/24.PubMedCrossRefGoogle Scholar
  50. 50.
    Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92. Epub 2009/01/30.PubMedCrossRefGoogle Scholar
  51. 51.
    Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53–60. Epub 2010/02/02.PubMedCrossRefGoogle Scholar
  52. 52.
    Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail. 2012;18(8):626–34. Epub 2012/08/04.PubMedCrossRefGoogle Scholar
  53. 53.
    Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55(19):2062–76. Epub 2010/05/08.PubMedCrossRefGoogle Scholar
  54. 54.
    Shah RV, Truong QA, Gaggin HK, Pfannkuche J, Hartmann O, Januzzi JL, Jr. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. Eur Heart J. 2012. Epub 2012/05/31.Google Scholar
  55. 55.
    Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12(4):338–47. Epub 2010/01/26.PubMedCrossRefGoogle Scholar
  56. 56.
    Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group J Am Coll Cardiol. 2001;37(7):1781–7. Epub 2001/06/13.Google Scholar
  57. 57.
    Januzzi JL, Jr., Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. Eur Heart J. 2012. Epub 2012/06/30.Google Scholar
  58. 58.
    Xue Y, Clopton P, Peacock WF, Maisel AS. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011;13(1):37–42. Epub 2010/12/15.PubMedCrossRefGoogle Scholar
  59. 59.
    Masson S, Anand I, Favero C, Barlera S, Vago T, Bertocchi F, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125(2):280–8. Epub 2011/12/06.PubMedCrossRefGoogle Scholar
  60. 60.
    deFilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304(22):2494–502. Epub 2010/11/17.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Dieplinger B, Januzzi Jr JL, Steinmair M, Gabriel C, Poelz W, Haltmayer M, et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma–the Presage ST2 assay. Clin Chim Acta. 2009;409(1–2):33–40. Epub 2009/08/25.PubMedCrossRefGoogle Scholar
  62. 62.
    Rehman SU, Mueller T, Januzzi Jr JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. J Am Coll Cardiol. 2008;52(18):1458–65. Epub 2008/11/20.PubMedCrossRefGoogle Scholar
  63. 63.
    Ky B, French B, McCloskey K, Rame JE, McIntosh E, Shahi P, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011;4(2):180–7. Epub 2010/12/24.PubMedCentralPubMedCrossRefGoogle Scholar
  64. 64.
    Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122(14):1387–95. Epub 2010/09/22.PubMedCrossRefGoogle Scholar
  65. 65.
    de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60–8. Epub 2010/12/30.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA
  2. 2.Cardiology Division, Department of MedicineBostonUSA

Personalised recommendations